Week Of September 17, 2012: Pfizer Launches Joint Venture In China; Spectrum Sartorius Opens New Facility In Germany; And More - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Week Of September 17, 2012: Pfizer Launches Joint Venture In China; Spectrum Sartorius Opens New Facility In Germany; And More

ePT--the Electronic Newsletter of Pharmaceutical Technology

Pfizer and the Chinese pharmaceutical company Zhejiang Hisun Pharmaceuticals have launched Hisun-Pfizer Pharmaceuticals, a joint venture formed between the two companies to develop, manufacture, and commercialize off-patent pharmaceutical products in China and global markets. Read More

On Sept. 12, 2012, Sartorius opened its new facility in Guxhagen, Germany, for the manufacture of bioreactors following a one-year, EUR 18-million ($23.5 million) construction project. The 100,000-ft2 complex will serve clients in the biopharmaceutical industry and provide space for a high-tech manufacturing hall and offices for around 240 employees. Read More

Xcelience opened its new 24,000-ft2 facility in Tampa, Florida, on Sept. 14, 2012. The building will be used for primary and secondary packaging, labeling, distribution, and warehouse services. This is the company’s second facility in the Tampa Bay area, and the company says it will be audited and approved for domestic as well as European clinical trials. Read More

A roundup of additional company and people news from pharmaceutical and biopharmaceutical companies, their suppliers, and contract-service providers. Read More

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here